MedTrace Logo

Study Evaluating Rapamune in Transplant Recipients in the Nordic Countries

NCT00195195 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 66

Last updated 2012-01-31

No results posted yet for this study

Summary

The purpose of this study is to gather information about the long-term effects and safety of treatment with Rapamune in transplant patients.

Conditions

  • Transplantation

Interventions

DRUG

Sirolimus

Transplantation patients treated with sirolimus who consent to participate in the study (register)

Sponsors & Collaborators

  • Wyeth is now a wholly owned subsidiary of Pfizer

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Wyeth is now a wholly owned subsidiary of Pfizer

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-01-31
Primary Completion
2008-06-30
Completion
2008-06-30

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00195195 on ClinicalTrials.gov